- Home
- PCRX vs ORKA Comparison
PCRX vs ORKA Comparison
Compare PCRX & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ORKA
- Stock Information
- Founded
- PCRX 2006
- ORKA 2004
- Country
- PCRX United States
- ORKA United States
- Employees
- PCRX N/A
- ORKA N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PCRX Health Care
- ORKA Health Care
- Exchange
- PCRX Nasdaq
- ORKA Nasdaq
- Market Cap
- PCRX 1.2B
- ORKA 1.2B
- IPO Year
- PCRX 2011
- ORKA N/A
- Fundamental
- Price
- PCRX $22.76
- ORKA $26.50
- Analyst Decision
- PCRX Buy
- ORKA Strong Buy
- Analyst Count
- PCRX 5
- ORKA 7
- Target Price
- PCRX $32.40
- ORKA $42.86
- AVG Volume (30 Days)
- PCRX 479.4K
- ORKA 600.7K
- Earning Date
- PCRX 11-05-2025
- ORKA 11-12-2025
- Dividend Yield
- PCRX N/A
- ORKA N/A
- EPS Growth
- PCRX N/A
- ORKA N/A
- EPS
- PCRX N/A
- ORKA N/A
- Revenue
- PCRX $705,848,000.00
- ORKA N/A
- Revenue This Year
- PCRX $7.36
- ORKA N/A
- Revenue Next Year
- PCRX $10.07
- ORKA N/A
- P/E Ratio
- PCRX N/A
- ORKA N/A
- Revenue Growth
- PCRX 2.25
- ORKA N/A
- 52 Week Low
- PCRX $16.00
- ORKA $5.49
- 52 Week High
- PCRX $27.64
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- PCRX 35.28
- ORKA 73.31
- Support Level
- PCRX $24.31
- ORKA $24.46
- Resistance Level
- PCRX $26.05
- ORKA $29.20
- Average True Range (ATR)
- PCRX 0.82
- ORKA 2.16
- MACD
- PCRX -0.20
- ORKA 0.75
- Stochastic Oscillator
- PCRX 18.36
- ORKA 79.85
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.